Towards Healthcare
Antithrombin Market to Drive USD 640.37 Million by 2035

Antithrombin Market Secures Growth as Regulatory Approvals Increase

According to forecasts, the global antithrombin market will grow from USD 420.33 million in 2025 to USD 640.37 million by 2035, with an expected CAGR of 4.3%. The antithrombin market is driven by technological advancements across the various steps involved in its production. North America is leading the market due to the strong presence of the pharmaceutical industry, where key players focus on clinical trials and strategic collaborations, boosting market growth. 

Content

  • Last Updated: 25 November 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2023
  • Base Year: 2024
  • Estimated Years: 2025-2034

About The Author

Rohan Patil is a seasoned market research professional with over 5 years of focused experience in the healthcare sector, bringing deep domain expertise, strategic foresight, and analytical precision to every project he undertakes.

He began his journey with Precedence Research, where he played a pivotal role in developing high-impact healthcare market reports. Today, Rohan leads research initiatives at Towards Healthcare, while also contributing to Statifacts, where he supports cross-industry analysis and data-driven storytelling.

Rohan’s core strengths lie in trend analysis and emerging technologies, regulatory monitoring and thought leadership through high-quality report writing. He excels at identifying future-ready opportunities and translating complex data into strategic recommendations. His work spans pharmaceuticals, biotechnology, medical devices, and digital health, assessing everything from market potential and competitive positioning to customer needs and regulatory shifts.

A trusted advisor and a relentless innovator, Rohan continues to push the boundaries of traditional market research, merging scientific rigor with commercial insight to stay ahead in a fast-evolving healthcare landscape.

Talk to us
FAQ's

The antithrombin market holds a valuation of USD 438.4 million as of 2026, and will expand to USD 640.37 million by 2035, achieving a CAGR of 4.3% between 2026 and 2035.

North America is currently leading the antithrombin market share by 40% due to the rise in the prevalence of thrombosis.

The antithrombin market comprises 5 segments product type, end-user, administration source, distribution channel, and region.

Some key players include Grifols, CSL Behring, Takeda Pharmaceutical Company Limited, Octapharma AG, LFB, and Kedrion S.p.A.

Key trends include rising advancements in biologics and recombinant pharmaceutical products.

The FDA has approved it as an anticoagulant to prevent clots in patients with inherited antithrombin deficiency prior to, during, or following surgery or childbirth.

Certain drugs, such as anabolic steroids, as well as illnesses like acute hepatitis, hemophilia, kidney transplants, and bleeding disorders, can all result in elevated antithrombin.
Any Questions